Clinical Development & Data
Trial architecture, endpoints, recruitment, comparator signals, investigator interpretation, and the way evidence in respiratory will be read downstream.
Respiratory
ICG works across respiratory markets where clinical differentiation, inhaled and biologic delivery, guideline position, patient identification, device behavior, and field execution interact.
The work includes respiratory competitive intelligence, asthma and COPD development assessment, severe-asthma biologics, inhaler and connected-device landscapes, market access, launch scenarios, and longitudinal monitoring.
Therapy, Device and Pathway Are One Field.
Respiratory adoption rarely turns on efficacy alone. It is shaped by phenotype definition, guideline position, inhaler or injector configuration, prescriber habits, patient technique, exacerbation burden, reimbursement, and field execution.
ICG reconstructs the full field to show which clinical, device, access, and organizational dependencies will govern uptake and competitive response.
Decision Environments
Engagements begin at different points, but the governing constraints often cross the boundaries of the initial request.
Regulatory & Access Pathways
Filing logic, label conditions, evidence requirements, reimbursement, pathway position, and country-level adoption constraints.
Launch & Commercial Architecture
Market preparation, field-force and medical roles, account coverage, channel structure, patient support, and launch sequencing.
Manufacturing & Delivery
Capacity, supply, configuration, administration, device or site readiness, and the relationship between operational uncertainty and asset value.
Patient & Treatment Systems
Patient identification, referral patterns, specialist pathways, administration burden, monitoring, persistence, and continuity of treatment.
Longitudinal Competitive Monitoring
Clinical, regulatory, access, organization, and commercial signals reconstructed across multi-phase and multi-year programs.
Evidence Architecture
The evidence base is developed through source calls and interviews positioned close to the decisions, constraints, and operating conditions being reconstructed.
Clinical & Investigator Side
Key opinion leaders, principal investigators, study-site personnel, treating specialists, centers of excellence, diagnostic pathways, and investigator-side clinical teams.
Company-Side Sources
Clinical development, regulatory, medical affairs, CMC and manufacturing, market access, patient services, field leadership, commercial, and portfolio functions.
Access & Operating Systems
Payer and reimbursement environments, procurement, distribution, treatment centers, testing providers, administration systems, patient-support infrastructure, and local access pathways.
Triangulation
Interview evidence is tested against clinical, regulatory, manufacturing, access, and organizational signals and against the criteria used by reviewers, payers, clinicians, partners, and other decision-makers.
Selected Project Record
Selected engagements across respiratory.
The projects below are selected from a substantially larger body of work. They were chosen to illustrate different decision environments, lifecycle stages, modalities, geographies, and forms of engagement. The selection is illustrative rather than exhaustive. Multi-phase and longitudinal assignments may be presented as a single project title, and company, asset, or market details may be generalized where appropriate.
Clinical Development & Data
- Clinical-Development and Recruitment Monitoring in Idiopathic Pulmonary Fibrosis
- Clinical-Readout and Launch-Scenario Assessment for Triple Therapy in Asthma
- Competitive Development Assessment of Anti-IL-5 Therapies in Asthma and COPD
- Clinical-Positioning Assessment for Biologic Therapies in Severe Asthma
Regulatory, Access & Adoption
- Market-Access and Guideline Architecture for Severe-Asthma Biologics in Europe
- Payer and Prescriber Response to Triple Therapy in Asthma in the United States
- Patient-Identification and Referral Architecture in Severe Asthma
- Access and Adoption Assessment for Idiopathic-Pulmonary-Fibrosis Therapies
Launch & Commercial Architecture
- Competitive and Launch Assessment of Biologic Therapies for Severe Asthma in the United States and Europe
- Four-Month Competitive Architecture of COPD Across the United States and the EU5
- Field-Force and Medical-Organization Benchmarking in Asthma and COPD
- Market Assessment of Neonatal Pulmonary Surfactants in China
Manufacturing, Delivery & Systems
- Digital-Inhaler and Connected Respiratory-Device Landscape
- Inhaler-Device Deep Dive for Asthma and COPD in Europe
- Self-Injection and Device Strategy for Respiratory Biologics
- Manufacturing and Supply Assessment for Inhaled Combination Therapies
Longitudinal Monitoring & Portfolio
- Longitudinal Competitive Monitoring Across Asthma and COPD Portfolios
- Multi-Year Monitoring of Severe-Asthma Biologics and Launch Scenarios
- Competitive Monitoring of Chronic-Cough Development Programs
- Respiratory Market and Device Monitoring Across Europe and the United States
Respiratory Engagements
ICG can enter at the level of a single critical question, a multi-market evidence program, or a longitudinal clinical, regulatory, manufacturing, access, commercial, or operating-system decision environment.